Nocturnal hypertension in type 2 DM
Conditions
Interventions
Losartan / hydrochlorothiazide group
ARB and CCB group
Sponsors
Kobe University Graduate School of Medicine Division of deabetes, metabolism and endocrinology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Hypertensive diabetic patients, who have been treated with ARB and Carcium channnel blocker for more than 4weeks, but not reached systolic blood pressure to 150 mmHg and /or diastolic blood pressure to 100 mmHg 2) aged more than 20 years 3) men and women 4) patients who fully understand the study procedures explained to them using explanatory notes and have given written informed consent to patients in the study
Exclusion criteria
Exclusion criteria: 1) patients with secondary hypertension 2) patients with liver dysfunction (GPT over three times the normal value) 3) patients with renal failure (serum creatinine over 2.0 mg/dL) 4) patients with bilareral renal artery stenosis 5) pregnant or possible pregnant women 6) patients with a history of hypersensitivity to Losartan or thiazide
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in nocturnal blood pressure level after 12 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| change in blood pressure level on an outpatient basis after 4,8 weeks of treatment change after12 weeks about HbA1c, fasting bllod glucose level, urine alubimin excretion, Urine Na, Crine K, renin, aldsterone, BNP, serum K, serum Na, serum UA, serum Creatinine, eGFR, LDL-C, TG, HDL-C | — |
Countries
Japan
Contacts
Public Contactkazuhiko sakaguchi
Kobe University Graduate School of Medicine Division of deabetes, metabolism and endocrinology
Outcome results
None listed